T1	HMM 0 19	Efficacy and safety
T2	HMM 528 547	efficacy and safety
T3	HMM 1251 1349	change in neuropathy between baseline and week 48, demonstrated by the Neuropathy Impairment Score
T4	HMM 1438 1692	quantitative sensory tests using the CASE IV System, the Neuropathy Symptom and Change questionnaire, the Patient Benefit Questionnaire (PBQ), and a global symptom assessment, as well as nerve conduction studies and occurrence of new plantar foot ulcers.
T5	HMM 1738 1753	adverse events.
T6	HMM 1918 1932	adverse events
T7	HMM 1978 2026	site pain/hyperalgesia and other pain syndromes.
T8	HMM 2177 2202	global symptom assessment
